88%Confidence
0Views
FDASource
2026-03-27Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validation processes before distribution represents a significant regulatory violation for a high-demand diabetes/weight loss drug component, potentially creating supply chain disruptions for compounding pharmacies. This highlights risks in the semaglutide supply chain and may lead to increased scrutiny of Chinese API manufacturers.
Actionable: Compounding pharmacies should immediately audit their semaglutide API sources and verify proper validation documentation from all suppliers.
AI Confidence: 88%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now